Skip to main content

Table 1 30 top-selling agents on PRISCUS list (Prices in €, Reference year 2009)

From: Potentially inappropriate medication in the elderly in Germany: an economic appraisal of the PRISCUS list

   

Aged 65 and above

Entire SHI population

Ratio aged ≥65 and entire SHI

No.

ATC-Code

Agent

DDD (in Mio.) ≥65 years

Prescriptions ≥65 (in Mio.)

Sales ≥65 (in Mio. €)

Costs per DDD ≥65

Total DDD (in Mio)

Total prescriptions (in Mio)

Total sales (in Mio. €)

Costs per DDD

DDD

Prescriptions

Sales

1

C02CA04

Doxazosin

51.4

0.56

19.5

0.38 €

60.2

0.81

28.1

0.38 €

85.38 %

69.47 %

69.37 %

2

N06AA09

Amitriptyline

45.7

1.13

19.8

0.43 €

94.5

2.28

40.5

0.43 €

48.36 %

49.66 %

48.88 %

3

C07AA07

Sotalol

34.0

0.53

10.2

0.30 €

36.6

0.68

13.0

0.30 €

92.90 %

78.39 %

78.56 %

4

C01AA02

Acetyldigoxin

32.5

0.93

11.7

0.36 €

36.4

1.05

13.3

0.36 €

89.29 %

88.62 %

88.06 %

5

N05CF01

Zopiclona

28.0

1.44

21.5

0.77 €

47.3

2.62

38.7

0.79 €

59.20 %

54.87 %

55.56 %

6

M01AH05

Etoricoxib

25.2

0.50

30.6

1.21 €

51.7

1.07

62.4

1.21 €

48.74 %

46.61 %

49.04 %

7

N06AA12

Doxepin

24.2

0.77

13.1

0.54 €

54.2

1.68

29.1

0.52 €

44.65 %

45.71 %

45.07 %

8

G04BD08

Solifenacin

22.6

0.24

32.5

1.44 €

31.3

0.33

44.8

1.43 €

72.20 %

72.84 %

72.54 %

9

N05CF02

Zolpidema

21.3

1.09

16.3

0.77 €

32.5

1.81

26.7

0.78 €

65.54 %

60.36 %

61.14 %

10

N06BX03

Piracetam

18.3

0.41

8.2

0.45 €

20.6

0.48

9.7

0.45 €

88.83 %

85.85 %

84.86 %

11

C04AD03

Pentoxifylline

15.0

0.35

7.2

0.48 €

17.7

0.57

11.0

0.54 €

84.75 %

61.29 %

65.61 %

12

N05BA08

Bromazepam

14.9

0.66

8.6

0.58 €

21.2

1.04

13.5

0.60 €

70.28 %

63.40 %

63.65 %

13

N06AA06

Trimipramine

14.6

0.49

10.8

0.74 €

31.6

1.12

24.5

0.73 €

46.20 %

43.66 %

44.17 %

14

N05BA01

Diazepam

13.1

0.53

6.0

0.46 €

31.0

1.30

15.3

0.47 €

42.26 %

40.71 %

39.16 %

15

N05CD06

Lormetazepama

12.5

0.38

5.2

0.42 €

15.3

0.51

7.0

0.42 €

81.70 %

74.50 %

74.20 %

16

C02CA08

Terazosin

12.3

0.19

6.6

0.54 €

8.0

0.24

8.2

0.56 €

-b

-

-

17

C02AC01

Clonidine

11.7

0.33

5.9

0.50 €

17.7

0.71

13.5

0.34 €

66.10 %

46.72 %

43.86 %

18

C02LA01

Reserpine and Diuretics

11.3

0.12

4.7

0.42 €

13.1

0.14

5.5

0.42 €

86.26 %

88.82 %

85.45 %

19

C01BC04

Flecainide

9.7

0.22

11.4

1.18 €

14.1

0.34

17.5

1.17 €

68.79 %

64.05 %

65.30 %

20

G04BD04

Oxybutynin

9.3

0.30

8.8

0.95 €

11.3

0.45

15.1

0.95 €

82.30 %

66.64 %

58.14 %

21

M01AC06

Meloxicam

9.3

0.21

3.3

0.35 €

14.8

0.41

6.3

0.38 €

62.84 %

50.66 %

52.12 %

22

N06AB03

Fluoxetine

8.8

0.10

2.9

0.33 €

43.3

0.58

17.3

0.32 €

20.32 %

17.32 %

16.79 %

23

M01AB01

Indometacin

8.7

0.25

4.0

0.46 €

14.2

0.53

8.6

0.48 €

61.27 %

47.36 %

46.63 %

24

C01AA08

Metildigoxin

8.4

0.17

2.7

0.32 €

9.5

0.20

3.0

0.32 €

88.42 %

86.65 %

90.00 %

25

M03BX07

Tetrazepam

8.3

0.57

8.0

0.96 €

22.0

2.08

26.8

1.19 €

37.73 %

27.46 %

29.90 %

26

C04AX21

Naftidrofuryl

7.5

0.34

8.2

1.09 €

9.0

0.43

10.2

1.11 €

83.33 %

78.49 %

80.17 %

27

C08CA05

Nifedipinea

6.5

0.26

3.8

0.58 €

69.7

1.32

22.2

0.29 €

9.33 %

19.70 %

17.11 %

28

M01AB11

Acemetacin

6.4

0.16

4.9

0.77 €

9.8

0.28

8.3

0.80 €

65.31 %

56.34 %

58.76 %

29

M03BX01

Baclofen

6.0

0.26

5.2

0.87 €

17.1

0.66

16.1

0.93 €

35.09 %

39.12 %

32.31 %

30

J01XE01

Nitrofurantoin

5.4

0.26

4.1

0.76 €

8.7

0.43

6.7

0.85 €

62.07 %

59.99 %

61.45 %

Sum Top30

  

502.9

13.75

305.7

 

864.40

26.15

562.71

 

58.18 %

52.59 %

54.33 %

Sum all 83 agents

  

598.7

16.93

387.8

 

1,124.00

37.71

1,037.37

 

53.27 %

44.89 %

37.38 %

  1. aPRISCUS agents which are potentially inappropriate at certain dose or release form
  2. bThe PPR does include the 3,000 top-selling drugs. Several traded products with terazosin as agent are sold less frequently and therefore not included. The published amount of DDD of terazosin is lower than the share of DDD taken by the elderlies. Consequently, calculation is misleading